Drug Trial Radar · NCT07796477
A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Nov 6, 2026
Primary completion
Sep 28, 2027
Study completion Oct 19, 2027
Sponsor
- Lead sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo and active-controlled, dose-finding phase 2 study aimed to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SYH2069 Injection in participants with Type 2 Diabetes Mellitus (T2DM) inadequate glycemic control with diet and exercise alone or metformin monotherapy. The study consists of four periods: a 2-week screening period, a 3-week run-in period, a 28-week treatment period and a 3-week safety follow-up period. A total of 240 subjects will be enrolled. All subjects will be stratified by baseline HbA1c levels (≤8.5% or \>8.5%) and prior metformin use (yes or no) , then randomized 4:1:4:1:4:1:4:1:4 to SYH2069 group 1, SYH2069 group 1 placebo, SYH2069 group 2, SYH2069 group 2 placebo, SYH2069 group 3, SYH2069 group 3 placebo, SYH2069 group 4, SYH2069 group 4 placebo and Tirzepatide injection 15mg, with 40 participants in each SYH2069 or Tirzepatide group and 10 participants in each SYH2069 placebo group. All treatment groups will implement dose titration to achieve the target dose.
Conditions
- T2DM (Type 2 Diabetes Mellitus)
Interventions
SYH2069 Injection (group 1)Drug
administered subcutaneously (SC), Once-Weekly (QW), 28 weeks
SYH2069 Injection (group 2)Drug
administered SC, QW, 28 weeks
SYH2069 Injection (group 3)Drug
administered SC, QW, 28 weeks
SYH2069 Injection (group 4)Drug
administered SC, QW, 28 weeks
SYH2069 Injection placeboDrug
administered SC, QW, 28 weeks
Tirzepatide Injection 15mgDrug
administered SC, QW, 28 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Hemoglobin A1c (HbA1c)Time frame: Baseline,Week 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.